Karyopharm Therapeutics Inc  

(Public, NASDAQ:KPTI)   Watch this stock  
Find more results for KPTI
+1.10 (4.07%)
Real-time:   1:57PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.03 - 28.64
52 week 23.86 - 49.01
Open 27.34
Vol / Avg. 311,699.00/298,430.00
Mkt cap 975.21M
P/E     -
Div/yield     -
EPS -2.33
Shares 35.64M
Beta     -
Inst. own 59%
Feb 23, 2015
Karyopharm Therapeutics Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 12, 2015
Karyopharm Therapeutics Inc at Leerink Global Healthcare Conference
Jan 13, 2015
Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference
Dec 11, 2014
Karyopharm Therapeutics Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -93923.81% -8771.83%
Operating margin -94019.05% -8772.61%
EBITD margin - -8735.40%
Return on average assets -42.44% -42.56%
Return on average equity -44.01% -49.91%
Employees 31 -
CDP Score - -


85 Wells Ave
NEWTON, MA 02459-3298
United States - Map
+1-617-6580600 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The Company has discovered and developed small molecule, Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein XPO1. The Company´┐Żs drug candidate, Selinexor (KPT-330), is an XPO1 inhibitor, evaluated in multiple open-label Phase 1 clinical trials in patients with heavily pretreated relapsed or refractory hematological and solid tumor malignancies. As of September 20, 2013, the Company had administered Selinexor to over 170 patients in these trials.

Officers and directors

Sharon Shacham Ph.D. President, Co-Founder, Chief Scientific Officer, Director
Age: 43
Bio & Compensation  - Reuters
Michael G. Kauffman M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Age: 50
Bio & Compensation  - Reuters
Justin A. Renz Chief Financial Officer, Executive Vice President
Age: 42
Bio & Compensation  - Reuters
Dilara McCauley Ph.D. Vice President - Product Leadership
Bio & Compensation  - Reuters
Brian Austad Ph.D. Senior Director, Head - Pharmaceutical Sciences
Bio & Compensation  - Reuters
J. Scott Garland Director
Age: 45
Bio & Compensation  - Reuters
Barry E. Greene Director
Age: 50
Bio & Compensation  - Reuters
Mansoor Raza Mirza M.D. Director and Clinical Advisor
Bio & Compensation  - Reuters
Deepa R. Pakianathan Ph.D. Director
Age: 49
Bio & Compensation  - Reuters
Kenneth E. Weg Director
Bio & Compensation  - Reuters